Is Syndax Pharmaceuticals Inc (SNDX) overvalued? · rev $137.7M
Syndax Pharmaceuticals Inc (SNDX) is a biotechnology company listed on US.
This page asks whether Syndax Pharmaceuticals Inc (SNDX) looks expensive on cached numbers — not a short thesis.
Latest reported SNDX revenue for 2026-06-30 was $137.7M. Net income was -$92.0M. SNDX currently screens at market cap $774.4M.
SNDX currently screens at market cap $774.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SNDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SNDX stock page for the full model, not this heading.
Not investment advice.